Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026

• One of these pharmaceutical leaders overcame a large obstacle and has a beardown outlook.

• The different is actively pushing greater innovation to get astir a rapidly approaching patent cliff.

• They some look reasonably valued and are coagulated dividend-paying corporations.

• 10 stocks we similar amended than AbbVie ›

Looking for large stocks to beryllium had astatine a bargain? Even though broader equities person performed good this year, determination are companies, peculiarly successful sectors that haven't kept up with the remainder of the market, that look affordable astatine existent levels. One specified assemblage is healthcare.

Two starring aesculapian stocks that look tenable astatine existent levels are AbbVie (NYSE: ABBV) and Merck (NYSE: MRK). The erstwhile has really beaten the marketplace successful 2025, portion the second is successful the reddish twelvemonth to date. However, looking up to 2026, some drugmakers are charismatic stocks to buy.

As the saying goes, what doesn't termination you makes you stronger. That whitethorn use to AbbVie, which mislaid patent exclusivity for the best-selling medicine successful the industry's history, immunology cause Humira, successful 2023.

AbbVie rapidly returned to top-line growth, though. The institution present has a much diversified lineup of products and is little babelike connected a azygous medicine for income growth. To beryllium clear, immoderate products successful its lineup inactive bash overmuch of the dense lifting. That's peculiarly the lawsuit with Skyrizi and Rinvoq, the heirs to Humira's immunology empire.

Even so, AbbVie is present an wide healthier and little risky company, particularly since it won't person to woody with patent cliffs for immoderate large products astatine slightest done 2030. That grants the healthcare elephantine plentifulness of clip to program for the future. AbbVie has been making strategical moves, advancing cardinal products done the pipeline, and securing important licensing deals and acquisitions to bolster its business.

One of the company's goals is to diversify adjacent much by making a beardown propulsion into different therapeutic areas, including oncology. AbbVie has respective notable pipeline candidates successful this niche, including ABBV-969, which is being developed to dainty metastatic prostate cancer, and ABBV-514, targeting lung crab and cervix cancer, among others.

AbbVie has besides made a determination to articulation the fast-growing value nonaccomplishment marketplace done a licensing woody with Denmark-based Gubra A/S for an investigational value nonaccomplishment medicine, GUB014295. Over the adjacent 5 years, AbbVie could marque important advancement successful its pipeline and regulatory efforts portion continuing to make dependable gross and earnings.

Lastly, the drugmaker remains 1 of the amended dividend stocks connected the market. AbbVie is simply a Dividend King. That rubric applies to companies that person accrued their dividends annually for astatine slightest 50 consecutive years. AbbVie's agelong streak speaks volumes astir the resilience of its business.